Breaking News, Financial News

Financial Report: Elan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 2Q Revenues: $136.4 million (+15%) 2Q Loss: $90.5 million (loss of $142.6 million 2Q2005) YTD Revenues: $270.7 million (+22%) YTD Loss: $123.8 million (loss of $258.2 million YTD2005) Comments: The net loss for the quarter was down 37%, primarily due to growth in product revenue and improved operating margins. R&D spending was down 18% to $52.6 million in the quarter. The company launched Tysabri in Germany, Ireland, UK and Sweden and re-introduced it in the U.S. i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters